In order to compare the antileukemic efficacy of the BCL-2/BCL-XL/BCL-W inhibitor ABT737 and the hypomethylating agent azacitidine, both compounds were tested in Rag2−/−γc−/− mice xenografted with human JMML. Here, BCL2L1 is linked to juvenile myelomonocytic leukemia.